Brief: Essa Pharma Presents Updated Phase 1 Masofaniten (Epi-7386) Clinical Data At The 30Th Annual Prostate Cancer Foundation Scientific Retreat
26/10/2023 23:27
Oct 26 (Reuters) - ESSA Pharma Inc EPIX.O :
* ESSA PHARMA PRESENTS UPDATED PHASE 1 MASOFANITEN
(EPI-7386)
CLINICAL DATA AT THE 30TH ANNUAL PROSTATE CANCER FOUNDATION
SCIENTIFIC RETREAT
* ESSA PHARMA - COMBINATION OF MASOFANITEN +ENZALUTAMIDE
CONTINUES
TO BE WELL TOLERATED WITH DEEP AND DURABLE REDUCTIONS IN PSA IN
PATIENTS WITH MCRPC
Source text for Eikon: ID:nCNWyh9HSa
Further company coverage: EPIX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ESSA Pharma
See all newsBrief: Essa Securityholders Approve Acquisition By Xenotherapeutics
Brief: Essa Securityholders Approve Acquisition By Xenotherapeutics
Brief: ESSA Pharma Provides Update On Its Application To The Supreme Court Of British Columbia For Amended Interim Order
Brief: ESSA Pharma Amends Agreement with XenoTherapeutics
Brief: ESSA Pharma Amends Agreement with XenoTherapeutics